How Wyeth Plans to Make Prevnar a $3 Billion Vaccine
This article was originally published in RPM Report
Executive Summary
Wyeth's conjugated pneumococcal vaccine continues to break records. The company boldly says there is a lot of growth left, enough to take the product through $3 billion a year and perhaps to $4.5 billion. No vaccine has ever reached those heights. Can Wyeth pull it off?
You may also be interested in...
Halo Effect: Pandemic Response, Vaccines and Public Health
Can the vaccine industry ride its effort to protect the public from H1N1 flu virus to an elevated reputation with the public? And will reputation permit the vaccine segmetn to continue to bring out new premium-priced products supported by larger governemnt purchase programs around the world? Those are the type of "halo effect" questions being raised be the financial community in advance of the big swine flu response of 2009-2010.
FDA Has Full Plate This Fall For Vaccines: More Than H1N1
FDA faces the massive task of facilitaing the development and distribution of H1N1 vaccine in the autumn of 2009, but the agency also has some important pending applications for other vaccines in the same timeframe: Prevnar-13, Cervarix, and Gardasil for boys. Wall Street is not showing much excitement about the upcoming decisions. The applicatins could present some pleasant surprises and positive events for the sponsors.
FDA Has Full Plate This Fall For Vaccines: More Than H1N1
FDA faces the massive task of facilitaing the development and distribution of H1N1 vaccine in the autumn of 2009, but the agency also has some important pending applications for other vaccines in the same timeframe: Prevnar-13, Cervarix, and Gardasil for boys. Wall Street is not showing much excitement about the upcoming decisions. The applicatins could present some pleasant surprises and positive events for the sponsors.